Previous reports have suggested
that young-onset Crohn’s disease has several clinical
features that are distinct from those in adults
and it might have a relatively more complicated clinical course due to
associated growth and developmental problems [1-3]. However, most
studies came from the Western countries and they did not include adult
patients for comparison [4]. Data from Asian populations about
young-onset Crohn’s disease are few, particularly risk factors
predicting the development of complications during the clinical course
among different age groups [5].
In the current study, we sought to assess clinical
presentation, phenotypes according to the Montreal classification and
potential risk factors for complications in patients with young-onset
Crohn’s disease.
Method
Patient population: The study population
consisted of 79 consecutive patients with Crohn’s disease treated in
Tuen Mun Hospital(TMH) of Hong Kong from Jan 2000 to Dec 2012. The
diagnosis of Crohn’s disease was based on clinical, ileocolonoscopic,
histopathologic, and radiologic findings [6]. Single-balloon
enteroscopy, capsule endoscopy, fluoroscopy or both was performed when
disease of the small intestine was suspected. Crohn’s disease was
classified according to the Montreal classification [6]. Throughout this
study, young-onset was defined as individual aged
£16 years for onset
of Crohn’s disease. The disease location was determined at diagnosis and
its behavior was categorized during follow-up.
Data collection: The clinical records of these
patients were retrospectively reviewed to obtain:
(i) Demographic characteristics including
gender, smoking habits and body mass index(BMI) on presentation,
(ii) Symptoms at onset and significant
findings on physical examination
(iii) Laboratory parameters, such as
hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein
and serum albumin, and disease activity indices (Pediatric Crohn’s
Disease Activity Index[PCDAI] and Crohn’s disease Activity Index
[CDAI] in young-onset and adult-onset group respectively) on initial
presentation,
(iv) Prescription of 5-aminosalicylic acid
compounds, immunomodulators (6-mercaptopurine, azathioprine, and
methotrexate), and biologics such as monoclonal antibody against
tumor necrosis factor
a
(anti-TNF a)
(v) Complications including surgical
intervention
Statistical analysis: The data were compiled and
analyzed by use of the commercial Statistical Package for the Social
Sciences (SPSS) for Window (version17.0; SPSS Inc, Chicago, IL). All
continuous variables were expressed as median and interquartile
range(IQR). Categorical variables were reported as percent. The
chi-square test, Fisher’s exact test and Mann-Whitney U test were used
when appropriate. The Kaplan-Meier method was used to estimate the
cumulative complication rate of the two groups of patients, and the
log-rank test was used to test for statistical significance.
Multivariate Cox proportional hazards regression analysis was performed
to identify independent risk factors for development of complications.
Effects of potential risk factors (namely age
£16 years old, male
sex, smoking history, ileocolonic disease location, upper
gastrointestinal [GI] tract involvement, presence of perianal lesions,
³12 months on
delayed use of immunosuppressive therapy, surgery on initial
presentation) were quantified by calculating the hazard ratio (HR) and
confidence interval (CI) from the final Cox model. P value less
than .05 was considered statistically significant.
TABLE I Demographic, Clinical and Phenotypic Characteristics of Patients with Crohn’s Disease
Variable |
Young onset (n=11) |
Adult onset (n=68) |
P value |
Sex, male: female |
8:3 |
47:21 |
0.405 |
Duration of symptoms before
|
|
|
|
presentation, median week (IQR) |
17.2 (48) |
12 (22) |
0.348 |
Body mass index (kg/m2) |
17.32 (9.28)1 |
21.29 (5.5) |
0.019 |
Fever |
4 (36.36) |
10 (14.71) |
0.041 |
Weight loss |
8 (72.7%)2 |
20 (29.4%) |
0.003 |
Gastrointestinal manifestation |
|
|
|
Abdominal pain
|
11 (100%) |
55 (80.9%) |
0.056 |
Only presenting symptom |
5 (45.45%) |
11 (16.18%)3 |
0.013 |
Peri-rectal bleeding |
5 (45.5%) |
32 (47.1%)4 |
0.460 |
Diarrhoea |
4 (36.4%) |
37 (54.4%) |
0.136 |
Others
|
0 (0%) |
16 (23.5%)5 |
0.036 |
Extra-intestinal manifestation
|
|
|
|
Oral aphthous ulcers/stomatitis
|
5 (45.5%) |
15 (22.1%) |
0.049 |
Polyarthralgia |
2 (18.2%) |
9 (13.2%) |
0.330 |
Others |
2 (18.2%)6 |
3 (4.41%)7 |
0.041 |
Phenotypic characteristics8 |
|
|
|
L1/L2/L3 |
1 (9.1%)/ |
11 (16.2%)/ |
0.271 |
|
3 (27.3%)/ |
23 (33.8%)/ |
0.336 |
|
6 ( 54.5%)
|
32 (47.1%) |
0.323 |
L4 9 |
3 (27.3%) |
7 (10.3%) |
0.057 |
B1/2/3 |
7 (63.6%)/ |
39 (57.4%)/ |
0.352 |
|
2 (18.2%)/ |
9 (13.2%)/ |
0.330 |
|
2 (18.2%) |
20 (29.4%) |
0.159 |
Perianal lesions
|
7(63.6%) |
25 (36.8%) |
0.046 |
|
Skin tag/fistula/abscess |
1/3/3 |
4/13/8 |
Laboratory parameters |
|
|
|
Hemoglobin (g/dL) |
11 (2) |
12.5 (3.5) |
0.152 |
Albumin (g/L) |
36 (8) |
38 (8.5) |
0.391 |
Erythrocyte sedimentation
rate(mm/hr) |
64 (48) |
38 (35.5) |
0.13 |
C-reactive protein(mg/L) |
52 (35.4) |
20.5 (38.25) |
0.011 |
Note. Data are either median (IQR) or no. (%) of patients,
unless otherwise indicated. Boldface type indicates
statistical significance.1: Failure to thrive(n=5),
body height below 5th percentile(n=4)2: below the
third percentile of the mean(n=5) 3: acute pain with
rebound tenderness(n=7)4: hemodynamic instability
(n=5) 5: right lower quadrate mass (n= 6),
peritonitis (n=5), intestinal obstruction (n=5)6:
erythema nodosum (n=1), uveitis (n=1) 7: pyoderma
gangrenousm (n=1),uveitis(n=1),primary sclerosing cholangitis
(n=1) 8: A2, n=47(69.1%); A3, 21(30.9%) 9:
isolated L4 , Young (n=1), Adult(n=2) |
Results
Demographic and clinical characteristics: Among
79 patients with Crohn’s disease diagnosed in TMH, 11 (13.92%) of them
had disease onset with age ≤16
year old (range: from 11 to 16 year old). Median age at onset of
symptoms was 13 years (IQR, 4 years) versus 29 years (IQR, 19 years) in
the young and adult-onset group, respectively and there was no
significant difference between their median follow-up periods (8 years (
IQR, 5 years) vs 7 years (IQR, 9 years), P=0.884). In this
cohort, only two (2(2.9%) vs 0(0%), P 0.281) and nineteen
(19 (27.9%) vs 0(0%), P 0.023) patients from the
adult-onset group had family history of Crohn’s disease and active
smoking history before the disease onset. One young-onset patient
received empirically a course of anti-tuberculous therapy before making
the diagnosis of Crohn’s disease. Young-onset patients tended to have
upper GI tract involvement (L4) in which among them, these lesions were
as follows: one case with an isolated ileal stricture demonstrated in
small bowel barium enema examination, one case with granulomatous
inflammation in duodenal and jejunal mucosa revealed in upper endoscopic
examination and another case presented with acute abdomen with sign of
intestinal obstruction with an isolated granulomatous inflammatory mass
lesion at small bowel revealed in an exploratory laparotomy.
Oesophagogastroduodenoscopy (OGD) with histo-pathological assessment of
antral biopsy performed in another four young-onset patients did not
revealed any abnormality. In the adult group, twenty-seven of them had
OGD performed and the lesions were as follows: two cases with non-Helicobacter
pylori (HP) associated duodenal ulceration and two cases each with
HP associated gastric ulceration and antral gastritis.
Among the young – onset patients, median PCDAI at
which the diagnosis of Crohn’s disease was established was 30 (IQR,
12.5) in which four (36.36%) of them were in moderate-to-severe disease
activity (i.e. PCDAI >30); while in the adult-onset group, median
CDAI was 119 (IQR, 62.5) in which none of them were in moderate or above
in severity and only 16 (23.53%) of them were in mild activity (i.e.
CDAI:150-219) .
Treatment and outcomes: Overall, only 8 (10.1%)
patients had history of anti-TNFá exposure during the study period in
which it primarily acted as maintenance and rescue therapy in the young-
and adult-onset patients respectively. Despite maximum dosage of
immunosuppressive agents, two (18.18%) young-onset patients at age of 21
and 23 years old (i.e. 6 and 9 years of illness respectively)
required the anti-TNFa
maintenance therapy to control the disease activity. Of the two cases on
infliximab, lack of response was noted in one patient two years after
therapy and it was switched over to adalimumab with which remission was
attained and sustained for next five years. Though the complication
rates were similar between the two groups, it took significantly a
longer period of time (84 vs 24 month, P 0.018) to develop
in the young-onset group. The main complications were bowel perforation
and progressive stricturing Crohn’s disease causing intestinal
obstruction. Regarding the obstructive Crohn’s strictures in the
young-onset group, they were two cases of ileal, one case each of
ascending and descending colonic stricture. On the other hand, there are
eighteen obstructive strictures among the adult-onset patients with
their locations as follows: four cases each of anastomosis and ileum,
three cases of descending colon, two cases each of small intestine,
ileocecal region and ascending colon; and one case of rectum. Seven
(10.29%) of the adult-onset group had bowel perforation due to
progressive penetrating disease behavior whereas no bowel perforation
was reported in the young-onset group.
TABLE II Management and Clinical Outcomes of Patients with Crohn’s Disease
Management
|
Young onset(n=11) |
Adult onset (n=68) |
P value |
Medical therapy |
|
|
|
Oral 5-aminosalicylic acid |
7( 63.63%) |
68(100%)
|
0.000 |
Immunosuppressive therapy 1 |
9(81.8%) |
52 ( 76.5%) |
0.348 |
Time(month, IQR ) required to
start |
38.22(42.74) |
20.43(25.42) |
0.232 |
Side effect ( n, %) |
1(9.1)2 |
9(13.23)3 |
0.352 |
Anti-TNF a |
2( 18.18%)4 |
6(8.82%)5 |
0.169 |
Complications (n, %) |
5(45.5%) |
29(42.6%) |
0.429 |
Median time(month,IQR) to develop
|
84(141) |
24(77) |
0.018 |
Bowel stricture
|
4 |
18 |
|
Others |
16
|
117 |
|
Bowel resection (n,%)
|
3(27.3%) |
19(28.1%) |
0.480 |
Data are no. (%) of patients, unless otherwise indicated.
Boldface type indicates statistical significance.1:
all cases were AZA except : MTX (n=1) in young-onset , 6-MP
(n=3) and MTX (n=2) in adult group. 2:MTX
induced hepatitis3: reversible bone
marrow suppression (n=5), hepatitis (n=2) and cutaneous
rash (n=1) by AZA, MTX induced Pneumocystis pneumonia
(n=1) 4: maintenance therapy with
infliximab (n=1) and adalimumab (n=1)
5: rescue therapy for active disease
(n=5) and closure of fistula-in-ano (n=1).
6: abdominal abscess (n=1) 7:bowel
perforation(n=7), abdominopelvic abscess(n=2),severe
gastrointetinal bleeding (n=12) 6-mercaptopurine
(6-MP), azathioprine (AZA), methotrexate
(MTX). |
All three cases in the young-onset group with bowel
resection presented acutely with emergent operations performed and they
are as follows: ileal inflammatory mass causing intestinal obstruction
required small bowel resection, two cases required right hemicolectomy
with indication of right lower quadrant tenderness with peritonitis and
toxic mega-colon. Among the adult-onset patients, three cases had
obstructive small bowel disease treated with surgical resection and the
causes of intestinal obstruction included progressive ileal stricture,
inflammatory mass lesion of small intestine causing intussusception and
bezoar obstruction respectively. The other sixteen patients in the
adult-onset group had hemi-colectomy performed with indications
including penetrating disease causing bowel perforations in twelve cases
in which nine of them were complicated with abdominal abscess,
stricturing disease behavior resulting colonic obstruction and profuse
lower gastrointestinal bleeding in two cases respectively.
Kaplan-Meier analysis showed that the cumulative rate
of complications over the disease course was statistically significant
difference (Log rank test, P 0.035) between the two groups. After
eliminating effect of confounding variables, Cox proportional hazard
regression analysis revealed that active smoking (hazard ratio[HR],
4.68; 95% confidence interval [CI]:1.03-4.09; P 0.045) and
delayed use of immuno-suppressive therapy (HR, 4.13; 95% CI: 1.01-16.88;
P 0.048) were the only independent risk factors associated with
increased risk of complications while age at diagnosis did not reach a
significant level in the multi-variate model (HR, 0.47; 95% CI:
0.13-1.66; P 0.24).
Discussion
This study revealed that young-onset Crohn’s disease
had distinct clinical features as compared with adult-onset type,
particularly abdominal pain ,fever and weight loss as an important triad
of symptoms in the young-onset ;but there were no significant difference
in the complication and bowel resection rate between the two groups.
The distinct clinical profiles of the two groups
might be due to differential impact of lengthy duration of presenting
symptoms according to their age of presentation [3]. In young patients,
this would cause progressive weight loss, low BMI and growth failure via
the long standing effect of chronic illness and malabsorption while in
the adult-onset, this, due to their poor awareness of the illness,
resulted in considerable amount of patients presented acutely, such as
severe lower GI bleeding, peritonitis and intestinal obstruction. The
higher prevalence of oral manifestation in the pediatric group might be
accounted by the indirect effect of Crohn’s disease via malabsorption.
In congruent with the previous Asian studies, ileo-colonic disease was
the most common disease location [2,4,7-10]. In our study, we
highlighted two distinct phenotypic characteristics in the pediatric
group. Firstly, the frequency of upper GI disease was higher than that
of the adult group [11]. This is explained by fluoroscopic examination
of upper GI tract more widely performed in our pediatric cohort.
Secondly, perianal lesion was also found more frequently. In fact, the
higher proportion of upper GI and perianal involvement in pediatric
patients was also observed in the other Asian studies [4,11,12].
Previous studies reported that Crohn’s disease runs a
more aggressive course in young population and the underlying reason
might be related to the evolution from inflammatory behavior to a more
complicated behavior (stricturing or penetrating) which is well
demonstrated in the Western literatures as well as another Hong Kong
study [10,13]. However, this association was failed to demonstrate in
our cohort. Instead, there was significant delay in complication
development in the pediatric group. This might be related to more widely
use of immuno-suppressive therapy in our pediatric group. In our study,
only smoking and delay use of immunosuppressive therapy were found to be
significantly associated with complication development.
This study enables us to better understand the
characteristics of young-onset Crohn’s disease and provide better
clinical care for them. The limitations of this study are its
retrospective design and single-centre data.
Acknowledgment: Ms Annie LK Choi for
proofreading.
Contributors: STL and KKL: Patient care; STL:
Conception and writing of the manuscript. All authors read and approved
the final manuscript.
Funding: None; Competing interests: None
stated.
What This Study Adds?
• Young-onset Crohn’s disease has distinct
clinical features as compared adult-onset type but it does not
carry higher risk of complications.
|
References
1. Mamula P,
Markowitz JE, Baldassano RN. Inflammatory bowel disease in early
childhood and adolescence: special considerations. Gastroenterol
Clin North Am. 2003; 32:967-95. viii.
2. Sauer CG, Kugathasan S.
Pediatric inflammatory bowel disease: highlighting pediatric
differences in IBD. Gastroenterol Clin North Am. 2009;38:611-28.
3. Avinash B, Dutta AK, Chacko A.
Pediatric inflammatory bowel disease in South India. Indian Pediatr.
2009;46: 639-40.
4. Ishige T, Tomomasa T,
Takebayashi T, Asakura K, Watanabe M, Suzuki T, et al.
Inflammatory bowel disease in children: epidemiological analysis of
the nationwide IBD registry in Japan. J Gastroenterol.
2010;45:911-7.
5. Treepongkaruna S, Pienvichit
P, Sornmayura P, Pornkul R, Wisedopas N, Phuapradit P.. Inflammatory
bowel disease in Thai children: presentations and outcomes of
treatment. Asian Pac J Allergy Immunol. 2006;24:73-9.
6. Satsangi J, Silverberg MS,
Vermeire S, Colombel JF. The Montreal classification of inflammatory
bowel disease: controversies, consensus, and implications. Gut.
2006;55:749-53.
7. Su CG, Judge TA, Lichtenstein
GR. Extraintestinal manifestations of inflammatory bowel disease.
Gastroenterol Clin North Am. 2002 ;31:307-27 .
8. Shin DH, Sinn DH, Kim YH, Kim
JY, Chang DK, Kim EJ, et al. Increasing incidence of
inflammatory bowel disease among young men in Korea between 2003 and
2008. Dig Dis Sci. 2011; 56:1154-9.
9. Song XM, Gao X, Li MZ, Chen
ZH, Chen SC, Hu PJ, et al. Clinical features and risk factors
for primary surgery in 205 patients with Crohn’s disease: analysis
of a South China cohort. Dis Colon Rectum. 2011;54:1147-54.
10. Chow DK, Leong RW, Lai LH,
Wong GL, Leung WK, Chan FK, et al. Changes in Crohn’s disease
phenotype over time in the Chinese population: validation of the
Montreal classification system. Inflamm Bowel Dis. 2008;14: 536-41.
11. Chow DK, Sung JJ, Wu JC, Tsoi
KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of
Crohn’s disease is associated with early surgery and further
hospitalization. Inflamm Bowel Dis. 2009;15:551-7.
12. Kim BJ, Song SM, Kim KM, Lee
YJ, Rhee KW, Jang JY, et al. Characteristics and trends in
the incidence of inflammatory bowel disease in Korean children: a
single-center experience. Dig Dis Sci. 2010;55:1989-95.
13. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA,
Belaiche J. Behaviour of Crohn’s disease according to the Vienna
classification: changing pattern over the course of the disease. Gut.
2001;49:777-82.